Polymorphisms of xenobiotic-metabolizing enzymes and susceptibility to cancer

Environmental Health Perspectives

Volumn 107, Issue SUPPL. 1, 1999, Pages 37-47

  Hirvonen, Ari ^a  

^a FINNISH INSTITUTE OF OCCUPATIONAL HEALTH   (Finland)

Author keywords

CYP1A1; CYP2D6; CYP2E1; Genetic polymorphisms; GSTM1; GSTM3; GSTP1; GSTT1; NAT1; NAT2

Indexed keywords

ACYLTRANSFERASE; EPOXIDE HYDROLASE; GLUTATHIONE TRANSFERASE; OXIDOREDUCTASE; XENOBIOTIC AGENT;

ALLELE; CANCER SUSCEPTIBILITY; DISEASE PREDISPOSITION; ENVIRONMENTAL EXPOSURE; ENZYME METABOLISM; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; PRIORITY JOURNAL; REVIEW; RISK FACTOR;

EID: 0032933160     PISSN: 00916765     EISSN: None     Source Type: Journal    
DOI: 10.1289/ehp.99107s137     Document Type: Review

References (212)

1. Vogelstein B, Kinzler KW. The multistep nature of cancer. Trends Genet 9:138-141 (1993).
2. Yuspa SH, Dlugosz AA, Cheng CK, Denning MF, Tannenbaum T, Glick AB, Weinberg WC. Role of oncogenes and tumor suppressor genes in multistage carcinogenesis. J Invest Dermatol 103:90S-95S (1994).
3. Sugimura T. Multistep carcinogenesis: a 1992 perspective. Science 258:603-607 (1992).
4. Kinzler KW, Vogelstein B. Life (and death) in a malignant tumour. Nature 379:19-20 (1996).
5. Hennings H, Glick AB, Greenhalgh DA, Morgan DL, Strickland JE, Tennenbaum T, Yuspa SH. Critical aspects of initiation, promotion, and progression in multistage epidermal carcinogenesis. Proc Soc Exp Biol Med 202:1-8 (1993).
6. Jackson MA, Stack HF, Waters MD. The genetic toxicology of putative nongenotoxic carcinogens. Mutat Res 296:241-277 (1993).
7. Barret JC. Mechanisms for species differences in receptor-mediated carcinogenesis. Mutat Res 333:189-202 (1995).
8. Costa M. Model for the epigenetic mechanism of action of nongenotoxic carcinogens. Am J Clin Nutr 61:666S-669S (1995).
9. Gonzalez FJ. Genetic Polymorphism and Cancer Susceptibility: Fourteenth Sapporo Cancer Seminar. Cancer Res 55:710-715 (1995).
10. Nebert DW, McKinnon RA, Puga A. Human drug-metabolizing enzyme polymorphisms: effects on risk of toxicity and cancer. DNA Cell Biol 15:273-280 (1996).
11. Kalow W. Pharmacogenetics: its biologic roots and the medical challenge. Clin Pharmacol Ther 54:235-241 (1993).
12. Daly AK, Cholerton S, Armstrong M, Idle JR. Genotyping for polymorphisms in xenobiotic metabolism as predictor of disease susceptibility. Environ Health Perspect 102:S44-S61 (1994).
13. Guengerich FP. Catalytic selectivity of human cytochrome P450 enzymes: relevance to drug metabolism and toxicity. Toxicol Lett 70:133-138 (1994).
14. Gonzalez FJ, Aoyama T, Gelboin HV. Activation of promutagens by human cDNA expressed cytochrome P450s. Prog Clin Biol Res 340B:77-86 (1990).
15. Eaton DL, Gallagher EP, Bammler TK, Kunze KL. Role of cytochrome P4501A2 in chemical carcinogenesis: implications for human variability in expression and enzyme activity. Pharmacogenetics 5:259-274 (1995).
16. Guengerich, FP, Kim DH, Iwasaki M. Role of human cytochrome P450 IIE1 in the oxidation of many low molecular weight cancer suspects. Chem Res Toxicol 4:168-179 (1991).
17. Shimada T, Yamasaki H, Mimura M, Inui Y, Guengerich FP. Interindividual variations in human liver cytochrome P450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. J Pharmacol Exp Ther 270:414-423 (1994).
18. Swanson HI, Bradfield CA. The AH-receptor: genetics, structure and function. Pharmacogenetics 3:213-230 (1993).
19. Fujii-Kuriyama Y, Ema M, Mimura J, Sogawa K. Ah receptor: a novel ligand-activated transcription factor. Exp Clin Immunogenet 11:65-74 (1994).
20. Gonzalez FJ. The CYP2D6 subfamily. In:Cytochromes P450s: Metabolic and Toxicologic Aspects (loannides C, ed.). Boca Raton, FL:CRC Press, 1996:183-210.
21. Daly AK, Brockmoller J, Broly F, Eichelbaum M, Evans WE, Gonzalez FJ, Huang J-D, Idle JR, Ingelman-Sundberg M, Ishizaki T, et al. Nomenlature for human CYP2D6 alleles. Pharmacogenetics 6:193-201 (1996).
22. Nelson DR, Koymans L, Kamataki T, Stegeman JJ, Feyereisen R, Waxman DJ, Waterman, MR, Gotoh O, Coon MJ, Astabrook RW, et al. P450 superfamily: update on new sequences, gene mapping, accession numbers and nomenclature. Pharmacogenetics 6:1-42 (1996).
23. Broly F, Gaedigk A, Heim M, Eichelbaum M, Morike K, Meyer UA. Debrisoquine/sparteine hydroxylation genotype and phenotype: analysis of common mutations and alleles of CYP2D6 in a European population. DNA Cell Biol 10:545-558 (1991).
24. Daly AK, Armstrong M, Monkman SC, Idle ME, Idle JR. Genetic and metabolic criteria for the assignment of debrisoquine 4-hydroxylation (cytochrome P4502D6) phenotypes. Pharmacogenetics 1:33-41 (1991).
25. Johansson I, Lundqvist E, Bertilsson L, Dahl MI, Sjöqvist F, Ingelman-Sundberg M. Inherited amplification of an active gene in the cytochrome P450 CYP2D locus as a cause of ultrarapid metabolism of debrisoquine. Proc Natl Acad Sci USA 90:11825-11829 (1993).
26. Meyer UA. Pharmacogenetics: the slow, the rapid, and the ultrarapid. Proc Natl Acad Sci USA 91:1983-1984 (1994).
27. Dahl M-L, Johansson I, Bertilsson L, Ingelman-Sundberg M, Sjöqvist F. Ultrarapid hydroxylation of debrisoquine in a Swedish population. Analysis of the molecular genetic basis. J Pharmacol Exp Ther 274:516-520 (1995).
28. Sachse C, Brockmöller J, Bauer S, Roots I. Cytochrome P450 2D6 variants in a Caucasian population: allele frequencies and phenotypic consequences. Am J Hum Genet 60:284-295 (1997).
29. Johansson I, Oscarson M, Vue Q-Y, Bertilsson L, Sjöqvist F, Ingelman-Sundberg M. Genetic analysis of the Chinese cytochrome P450D locus: characterization of variant CYP2D6 genes present in subjects with diminished capacity for debrisoquine hydroxylation. Mol Pharmacol 46:452-459 (1994).
30. Masimirembwa CM, Johansson I, Hasler JA, Ingelman-Sundberg M. Genetic polymorphism of cytochrome P450 CYP2D6 in a Zimbabwean population. Pharmacogenetics 3:275-280 (1993).
31. Agundéz JAG, Ledesma MC, Ladero JM, Benítez J. Prevalence of CYP2D6 gene duplication and its repercussion on the oxidative phenotype in white population. Clin Pharmacol Ther 57:265-269 (1995).
32. McLellan RA, Oscarson M, Seidegård J, Evans DAP, Ingelman-Sundberg M. Frequent occurrence of CYP2D6 gene duplication in Saudi Arabians. Pharmacogenetics 7:187-191 (1997).
33. Aklillu E, Persson I, Bertilsson L, Johansson I, Rodrigues F, Ingelman-Sundberg M. Frequent distribution of ultrarapid metabolizers of debrisoquine in an Ethiopian population carrying duplicated and multiduplicated functional CYP2D6 alleles. J Pharmacol Exp Ther 278:441-446 (1996).
34. Smith G, Stanley LA, Sim E, Strange R, Wolf CR. Metabolic polymorphisms and cancer susceptibility. Cancer Surv 25:27-65 (1995).
35. Nebert DW, Mckinnon RA, Puga A. Human drug-metabolizing enzyme polymorphisms: effects on risk of toxicity and cancer. DNA Cell Biol 15:273-280 (1996).
36. Rostami-Hodjegan A, Lenard MS, Woods HE, Tucker GT. Meta-Analysis of studies of the CYP2D6 polymorphism in relation to lung cancer and Parkinson's disease. Pharmacogenetics 8:227-238 (1998).
37. Bouchardy C, Benhamou S, Dayer P. The effect of tobacco on lung cancer risk depends on CYP2D6 activity. Cancer Res 56:251-253 (1996).
38. Rojas M, Camus AM, Alexandrov K, Husgafvel-Pursiainen K, Anttila S, Vainio H, Bartsch H. Stereoselective metabolism of (-)-benzo [a]pyrene-7,8-diol by human lung microsomes and peripheral blood lymphocytes: effects of smoking. Carcinogenesis 13:929-933 (1992).
39. Shou M, Krausz KW, Gonzalez FJ, Gelboin HV. Metabolic activation of the potent carcinogen dibenzo[a]pyrene by human recombinant cytochromes P450, lung and liver microsomes. Carcinogenesis 17:2429-2433 (1996).
40. Bartsch H, Rojas M, Alexandrov K, Camus A-M, Castegnaro M, Malaveille C, Anttila S, Hirvonen A, Husgafvel-Pursiainen K, Hietanen E, et al. Metabolic polymorphism affecting DNA binding and excretion of carcinogens in humans. Pharmacogenetics 5:S84-S90 (1995).
41. Kellermann G, Shaw CR, Luyten-Kellerman M. Aryl hydrocarbon hydroxylase inducibility and bronchogenic carcinoma. N Engl J Med 289:934-937 (1973).
42. Kawajiri K, Nakachi K, Imai K, Yoshii A, Shinoda N, Watanabe J. Identification of genetically high risk individuals to lung cancer by DNA polymorphisms of the cytochrome P4501A1 gene. FEBS Lett 263:131-133 (1990).
43. Hayashi SI, Watanabe J, Nakachi K, Kawajiri K. Genetic linkage of lung cancer-associated Mspl polymorphisms with amino acid replacement in the heme binding region of the human cytochrome P4501A1 gene. J Biochem 110: 407-411 (1991).
44. Cascorbi I, Brockmöller J, Roots I. A C4887A polymorphism in exon 7 of human CYP1A1: population frequency, mutation linkages, and impact on lung cancer susceptibility. Cancer Res 56:4965-4969 (1996).
45. Landi MT, Bertazzi PA, Shields PG, Clark G, Lucier GW, Garte SJ, Cosma G, Caporaso NE. Association between CYP1A1 genotype, mRNA expression and enzymatic activity in humans. Pharmacogenetics 4:242-246 (1994).
46. Crofts F, Taioli E, Cosma GN, Currie D, Toniolo P, Garte SJ. Functional significance of different human CYP1A1 genotypes. Carcinogenesis 15:2961-2963 (1994).
47. Persson I, Johansson I, Ingelman-Sundberg M. In vitro kinetics of two human CYP1A1 variant enzymes suggested to be associated with interindividual differences in cancer susceptibility. Biochem Biophys Res Commun 231:227-230 (1997).
48. Nebert DW. The Ah locus: genetic differences in toxicity, cancer, mutation and birth defects. CRC Crit Rev Toxicol 20:153-174 (1989).
49. Swanson HI, Bradfield CA. The AH-receptor: genetics, structure and function. Pharmacogenetics 3:213-230 (1993).
50. d'Errico A, Taioli E, Chen X, Vineis P. Genetic polymorphisms and the risk of cancer: a review of the literature. Biomarkers 1:149-173 (1996).
51. Kawajiri K, Nakachi K, Imai K, Watanabe J, Hayashi S. The CYP1A1 gene and cancer susceptibility. Crit Rev Oncol Hematol 14:77-87 (1993).
52. Sugimura H, Wakai K, Genka K, Nagura K, Igarashi H, Nagayama K, Ohkawa A, Baba S, Morris BJ, Tsugane S, et al. Association of lle462Val (exon 7) polymorphism of cytochrome P450 1A1 with lung cancer in the Asian population: further evidence from a case-control study in Okinawa. Cancer Epidemiol Biomarkers Prev 7:413-417 (1998).
53. Xu X, Kelsey KT, Wiencke JK, Wain JC, Christiani DC. Cytochrome P450 CYP1A1 Mspl polymorphism and lung cancer susceptibility. Cancer Epidemiol Biomarkers Prev 5:687-692 (1996).
54. 1450) gene: lack of association between the Mspl restriction fragment length polymorphism and incidence of lung cancer in a Norwegian population. Pharmacogenetics 1:20-25 (1991).
55. Hirvonen A, Husgafvel-Pursianen K, Karjalainen A, Anttila S, Vainio H. Point mutational Mspl and lle/Val polymorphism linked in the CYP1A1 gene: lack of association with susceptibility to lung cancer in a Finnish population. Cancer Epidemiol Biomarkers Prev 1:485-489 (1992).
56. Shields PG, Sugimura H, Caporaso NE, Petruzzelli SF, Bowman ED, Trump BF, Weston A, Harris CC. Polycyclic aromatic hydrocarbons-DNA adducts and the CYP1A1 restriction fragment length polymorphism. Environ Health Perspect 98:191-194 (1992).
57. Alexandrie A-K, Ingelman-Sundberg M, Seidegård J, Tomling G, Rannug A. Genetic susceptibility to lung cancer with special emphasis on CYP1A1 and GSTM1 a study on host factors in relation to age at onset, gender and histological cancer types. Carcinogenesis 15:1785-1790 (1994).
58. Bouchardy C, Wikman H, Benhamou S, Hirvonen A, Dayer P, Husgafvel-Pursiainen K. CYP1A1 genetic polymorphisms, tobacco smoking and lung cancer risk in a French Caucasian population. Biomarkers 2:131-134 (1997).
59. Ishibe N, Harkinson SE, Golditz GA, Spiegelman D, Willett WC, Speizer FE, Kelsey KT, Hunter D. Cigarette smoking, cytochrome P450 1A1 polymorphisms, and breast cancer risk in the Nurses' Health Study. Cancer Res 58:667-671 (1998).
60. Esteller M, Garcia A, Martinez-Palones JM, Xercavins J, Reventes J. Germ line polymorphisms in cytochrome-P450 1A1 (C4887 CYP1A1) and methylenetetra-hydrofolate reductase (MTHFR) genes and endometrial cancer susceptibility. Carcinogenesis 18:2307-2311 (1997).
61. Eaton DA, Gallagher EP, Bammler TK, Kunze KL. Role of cytochrome P4501A2 in chemical carcinogenesis: implications for human variability in expression and enzyme activity. Pharmacogenetics 5:259-274 (1995).
62. Ikeya K, Jaiswal AK, Owens RA, Jones JE, Nebert DW, Kimura S. Human CYP1A2 sequence, gene structure, comparison with the mouse and rat orthologous gene, and genetic differences in liver IA2 mRNA concentrations. Mol Endocrinol 3:1399-1408 (1989).
63. Butler MA, Lang NP, Yong JF, Caporaso NE, Vineis P, Hayes RB, Teitel CH, Massengill JP, Lawsen MF, Kadlubar FF. Determination of CYP1A2 and NAT2 phenotypes in human population by analysis of caffeine urinary metabolites. Pharmacogenetics 2:116-127 (1992).
64. llett KF, Castleden WM, Vandongen YK, Stacey MC, Butler MA, Kadlubar FF. Acetylation phenotype and cytochrome P4501A2 phenotype are unlikely to be associated with peripheral arterial disease. Clin Pharmacol Ther 54:317-322 (1993).
65. Fernandez-Salguero P, Gonzalez FJ. The CYP2A gene subfamily: species differences, regulation, catalytic activities and role in chemical carcinogenesis. Pharmacogenetics 5:S123-S128 (1995).
66. Fernandez-Salguero P, Hoffman SMG, Cholerton S, Mohrenweiser H, Raunio H, Rautio A, Pelkonen O, Huang J, Evans WE, Idle JR, et al. A genetic polymorphism in coumarin 7-hydroxylation: sequence of the human CYP2A genes and identification of variant CYP2A6 alleles. Am J Hum Genet 57:651-660 (1995).
67. Cholerton S, Idle ME, Vas A, Gonzalez FJ, Idle JR. Comparison of a novel thin layer chromatographic-fluorescence detection method with a spectrofluorometric method for the determination of 7-hydrocoumarin in human urine. J Chromatogr 575:325-330 (1992).
68. Rautio A, Kraul H, Kojo A, Salmela E, Pelkonen O. Interindividual variability of coumarin 7-hydroxylation in healthy volunteers. Pharmacogenetics 2:227-233 (1992).
69. Nunoya K, Yokoi T, Kimura K, Inoue K, Kodama T, Funayama M, Nagashima K, Funae Y, Green C, Kinoshita M, et al. A new deleted allele in the human cytochrome P450 2A6 (CYP2A6) gene found in individuals showing poor metabolic capacity to coumarin and (+)-cis-3,5-dimethyl-2-(3-pyridyl)thiazolidin-4-one hydrochloride (SM-12502). Pharmacogenetics 8:239-249 (1998).
70. Pianezza ML, Sellers EM, Tyndale RF. Nicotine metabolism defect reduces smoking [Letter to the Editor]. Nature 393:750 (1998).
71. 144C allelic variant of CYP2C9. Pharmacogenetics 4:39-42 (1994).
72. London SJ, Sullivan-Klose T, Daly AK, Idle JR. Lung cancer risk in relation to the CYP2C9 genetic polymorphism among Caucasians in Los Angeles County. Pharmacogenetics 7:401-404 (1997).
73. Ozawa S, McDaniel LP, Tang Y-M, Schoket B, Vincze I, Kostic S, Kadlubar FF. CYP2C9 and GSTP1 genetic polymorphisms in patients with smoking-related lung cancer [Abstract]. Proc Am Assoc Cancer Res 38:212P (1997).
74. Goldstein JA, Ishizaki T, Chiba K, De Morais SM, Bell D, Krahn PM, Evans DA. Frequencies of the defective CYP2C19 alleles responsible for the mephenytoin poor metabolizer phenotype in various Oriental, Caucasian, Saudi Arabian and American black populations. Pharmacogenetics 7:59-64 (1997).
75. McBride OW, Umeno M, Gelboin HV, Gonzalez FJ. A Taql polymorphism in the human P450IIE1 gene on chromosome 10 (CYP2E). Nucl Acid Res 15:10071 (1987).
76. Uematsu F, Kikuchi H, Ohmachi T, Sagami I, Motomiya M, Kamataki T, Komori M, Watanabe M. Two common RFLPs of the human CYP2E1 gene. Nucl Acid Res 19:2803 (1991).
77. Uematsu F, Kikuchi H, Motomiya M, Abe T, Sagami I, Ohmachi T, Wakui A, Kanamaru R, Watanabe M. Association between restriction fragment length polymorphism of the human cytochrome P450IIE1 gene and susceptibility to lung cancer. Jpn J Cancer Res 82:254-256 (1991).
78. Uematsu F, Kikuchi H, Abe T, Motomiya M, Ohmachi T, Sagami I, Watanabe M. Mspl polymorphism of the human CYP2E1 gene [Abstract]. Nucl Acids Res 19:5797 (1991).
79. Hayashi S, Watanabe J, Kawajiri K. Genetic polymorphisms in the 5′-flanking region change transcriptional regulation of the human cytochrome P450IIE1 gene. J Biochem (Tokyo) 110:559-565 (1991).
80. Watanabe J, Hayashi S, Kawajiri K. Different regulation and expression of the human CYP2E1 gene due to the Rsal polymorphisms in the 5′-flanking region. J Biochem (Tokyo) 116:321-326 (1994).
81. Peter R, Bocker R, Beaune PH, Iwasaki M, Guengerich FP, Yang CS. Hydroxylation of chlorzoxazone as a specific probe for human liver cytochrome P-450IIE1. Chem Res Toxicol 3:566-573 (1990).
82. Carriere V, Goasduff T, Ratanasavahn D, Morel F, Gautier JC, Guillouzo A, Beaune P, Berthou F. Both cytochromes P450IIE1 and 1A1 are involved in the metabolism of chlorzoxazone. Chem Res Toxicol 6:852-857 (1993).
83. Carriere V, Berthou F, Baird S, Belloc C, Beaune P, de Waziers I. Human cytochrome P450 IIE1 (CYP2E1): from genotype to phenotype. Pharmacogenetics 6:203-211 (1996).
84. Kim RB, O'Shea D, Wilkinson GR. Relationship in healthy subjects between CYP2E1 genetic polymorphisms and the 6-hydroxylation of chlorzoxazona: a putative measure of CYP2E1 activity. Pharmacogenetics 4:162-165 (1994).
85. O'Shea D, Davis SN, Kim RB. Effect of fasting and obesity in humans on the 6-hydroxylation of chlorzoxazone: a putative probe of CYP2E1 activity. Clin Pharmacol Ther 56:359-367 (1994).
86. Kim RB, O'Shea D. Interindividual variability of 6-hydroxylation of chlorzoxazone in men and women and its relationship to CYP2E1 genetic polymorphisms. Clin Pharmacol Ther 57:645-655 (1995).
87. Vessel ES, Seaton TD, A-Rahim YI. Studies on interindividual variations of CYP2E1 using chlorzoxazone as an in vivo probe. Pharmacogenetics 5:53-57 (1995).
88. Uematsu F, Kikuchi H, Motomiya M, Abe T, Ishioka C, Kanamaru R, Sagami I, Watanabe M. Human cytochrome P450IIE1 gene: Oral polymorphism and susceptibility to cancer. Tohoku J Exp Med 168:113-117 (1992).
89. Uematsu F, Ikawa S, Sagami I, Kanamaru R, Abe T, Satoh K, Motomiya M, Watanabe M. Restriction fragment length polymorphism of the human CYP2E1 (cytochrome P450IIE1) gene and susceptibility to lung cancer: possible relevance to low smoking exposure. Pharmacogenetics 4:58-63 (1994).
90. Hirvonen A, Husgafvel-Pursiainen K, Anttila S, Karjalainen A, Vainio H. The human CYP2E1 gene and lung cancer: Oral and Rsal restriction fragment lenght polymorphisms in a Finnish study population. Carcinogenesis 14:85-88 (1993).
91. Persson I, Johansson I, Ingelman-Sundberg M. In vitro kinetics of two human CYPIA1 variant enzymes suggested to be associated with interindividual differences in cancer susceptibility. Biochem Biophys Res Commun 231:227-230 (1997).
92. Hildesheim A, Anderson LM, Chen C-J, Brinton LA, Daly AK, Reed CD, Chen I-H, Caporaso NE, Hsu M-M, Chen J-Y, et al. CYP2E1 genetic polymorphisms and risk of nasopharyngeal carcinoma in Taiwan. J Natl Cancer Inst 89:1207-1212 (1997).
93. Oesch F. Mammalian epoxide hydrolases: inducible enzymes catalyzing the inactivation of carcinogenic and cytotoxic metabolites derived from aromatic and olefinic compounds. Xenobiotica 3:305-340 (1973).
94. Sims P, Grover PL, Swaisland A, Pal K, Hewer A. Metabolic activation of benzo(a)pyrene proceeds by a diol epoxide. Nature 252:326-328 (1974).
95. Oesch F, Glatt H, Schimassmann H. The apparent ubiquity of epoxide hydrolase in rat organs. Biochem Pharmacol 26:603-607 (1977).
96. Seidegård J, Ekström G. The role of human glutathione transferases and epoxide hydrolases in the metabolism of xenobiotics. Environ Health Perspect 105:791-799 (1997)
97. Omiecinski CJ, Aicher L, Holubkov R, Checkoway H. Human peripheral lymphocytes as indicators of microsomal epoxide hydrolase activity in liver and lung. Pharmacogenetics 3:150-158 (1993).
98. Etter H, Richter C, Ohta Y, Winterhalter KH, Sasabe H, Kawato S. Rotation and interaction with epoxide hydrolase of P-450 in proteoliposomes. J Biol Chem 266:18600-18605 (1991).
99. Hasset C, Robinson KB, Beck NB, Omiecinski CJ. The human microsomal epoxide hydrolase gene (EPHX1): complete nucleotide sequence and structural characterization. Genomics 23:433-442 (1994).
100. Hasset C, Aicher L, Sidhu JS, Omiecinski CJ. Human microsomal epoxide hydrolase: genetic polymorphism and functional expression in vitro of amino acid variants. Hum Mol Genet 3:421-128 (1994).
101. Raaka S, Hasset C, Omiecinski CJ. Human microsomal epoxide hydrolase: 5′-flanking region genetic polymorphism. Carcinogenesis 19:387-393 (1998)
102. 1. Proc Natl Acad Sci USA 92:2384-2387 (1995).
103. Lancaster JM, Browniee HA, Bell DA, Futreal A, Marks JR, Berchuck A, Wiseman RW, Taylor JA. Microsomal epoxide hydrolase polymorphism as a risk factor for ovarian cancer. Mol Carcinog 17:160-162 (1996).
104. Smith CAD, Harrison DJ. Association between polymorphism in gene for microsomal epoxide hydrolase and susceptibility to emphysema. Lancet 350:630-633 (1997).
105. Hayes JD, Pulford DJ. The glutathione S-transferase supergene family: regulation of GST and the contribution of the isoenzymes to cancer chemoprotection and drug resistance. Crit Rev Biochem Mol Biol 30:445-600 (1995).
106. Coles B, Ketterer B. The role of glutathione and glutathione transferases in chemical carcinogenesis. Crit Rev Biochem Mol Biol 25:47-70 (1990).
107. Seidegård J, Vorachek WR, Pero RW, Pearson WR. Hereditary differences in the expression of the human glutathione transferase active on trans-stilbene oxide are due to a gene deletion. Proc Natl Acad Sci USA 85:7293-7297 (1988).
108. Rebbeck TR. Molecular epidemiology of the human glutathione S-transferase genotypes GSTM1 and GSTT1 in cancer susceptibility. Cancer Epidemiol Biomarkers Prev 6:733-743 (1997).
109. London SJ, Daly AK, Cooper J, Navidi WC, Carpenter CL, Idle JR. Polymorphism of glutathione S-transferase M1 and lung cancer risk among African-Americans and Caucasians in Los Angeles county, California. J Natl Cancer Inst 87:1246-1253 (1995).
110. McWilliams JE, Sanderson BJ, Harris EL, Richert-Boe KE, Henner WD. Glutathione S-transferase M1 (GSTM1) deficiency and lung cancer risk. Cancer Epidemiol Biomarkers Prev 4(6):589-594 (1995).
111. Brockmöller J, Kerb R, Orakoulis N, Staffeldt B, Roots I. Glutathione S-transterase M1 and its variants A and B as host factors of bladder cancer susceptibility: a case-control study. Cancel Res 54:4103-4111 (1994).
112. Inskip A, Elexpuru-Camiruaga J, Buxton N, Dias PS, Macintosh J, Campbell D, Jones PW, Yengi L, Talbot JA, Strange RC, et al. Identification of polymorphism at the glutathione S-transferase, GSTM3 locus: evidence for linkage with GSTM1 *A Biochem J 312:713-716 (1995).
113. Anttila S, Hirvonen A, Vainio H, Husgafvel-Pursiainen K, Hayes JD, Ketterer B. Immunohistochemical localization of glutathione S-transferases in human lung. Cancer Res 53:5643-5648 (1993).
114. Anttila S, Luostarinen L, Hirvonen A, Elovaara E, Karjalainen A, Nurminen T, Hayes JD, Vainio H, Ketterer B. Pulmonary expression of glutathione S-transferase M3 in lung cancer patients: association with GSTM1 polymorphism, smoking, and asbestos exposure. Cancer Res 55:3305-3309 (1995).
115. Yengi L, Inskip A, Gilford J, Alldersea J, Bailey L, Smith A, Lear JT, Heagerty AH, Bowers B, Hand P, et al. Polymorphism at the glutathione S-transferase locus GSTM3: interactions with cytochrome P450 and glutathione S-transferase genotypes as risk factors for multiple cutaneous basal cell carcinoma. Cancer Res 56:1974-1977 (1996).
116. Jahnke V, Matthias C, Fryer A, Strange R. Glutathione S-transferase and cytochrome-P-450 polymorphism as risk factors for squamous cell carcinoma of the larynx. Am J Surg 172:671-673 (1996).
117. Matthias C, Bockmühl U, Jahnke V, Jones PW, Hayes JD, Alldersea J, Gilford J, Bailey L, Bath J, Wortall SF, et al. Polymorphism in cytochrome P450 CYP2D6, CYP1A1, CYP2E1 and glutathione S-transferase, GSTM1, GSTM3, GSTT1 and susceptibility to tobacco-related cancers: studies in upper aerodigestive tract cancers. Pharmacogenetics 8:91-100 (1998).
118. Jourenkova-Mirnova N, Wikman H, Bouchardy C, Voho A, Dayer P, Benhamou S, Hirvonen A. Role of glutathione S-transferase GSTM1, GSTM3, GSTP1, and GSTT1 genotypes in modulating susceptibility to smoking related lung cancer. Pharmacogenetics (in press).
119. Ali-Osman F, Akande N, Mao J. Molecular cloning, characterization, and expression in Eschericia coli of full-length cDNAs of three human glutathione S-transferase pi gene variants. Evidence for differential catalytic activity of the encoded proteins. J Biol Chem 272:10004-10012 (1997).
120. Zimniak P, Nanduri B, Piula S, Bandorowicz-Pikula J, Singhal S, Srivastava SK, Awasthi S, Awasrhi JC. Naturally occurring human glutathione S-transferase GSTP1.1 isoforms with isoleucine and valine at position 104 differ in enzymatic properties. Eur J Biochem 224:893-899 (1994).
121. Hu X, O'Donnel R, Srivastava SK, Xia H, Zimniak P, Nanduri B, Bleicher RJ, Awasthi S, Awasthi YC, Ji X, et al. Active site architecture of polymorphic forms of human glutathione S-transferase P1-1 accounts for their enantioselectivity and disparate activity in the glutathione conjugation of 7,8-dihydroxy-9,10-oxy-1.8.9,10-tetrahydrobenzo(a)pyrene. Biochem Biophys Res Commun 235:424-428 (1997).
122. Harries LW, Stubbins MJ, Forman D, Howard GCW, Wolf R. Identification of genetic polymorphisms at the glutathione S-transferase pi locus and association with susceptibility to bladder, testicular and prostate cancer. Carcinogenesis 18:641-644 (1997).
123. Matthias C, Bockmühl U, Jahnke V, Harries L, Wolf CR, Jones PW, Alldersea J, Worrall SF, Hand P, Fryer AA, et al. The glutathione S-transferase GSTP1 polymorphism: effects on susceptibility to oral/pharyngeal and laryngeal carcinomas. Pharmacogenetics 8:1-6 (1998).
124. Ryberg D, Skaug V, Hewer A, Phillips DH, Harries LW, Wolf CR, Øgreid D, Ulvik A, Vu P, Haugen A. Genotypes of glutathione transferase M1 and P1 and their significance for lung DNA adduct levels and cancer risk. Carcinogenesis 18:1285-1289 (1997).
125. Jaskula-Sztul R, Reinikainen M, Husgafvel-Pursiainen K, Szmeja Z, Szyfter W, Szyfter K, Hirvonen A. Glutathione S-transferase M1 and T1 genotypes as and susceptibility to smoking-related larynx cancer. Biomarkers 3:149-155 (1998).
126. Harris MJ, Coggan M, Langton L, Wilson SR, Board PG. Polymorphism of the Pi class glutathione S-transferase in normal populations and cancer patients. Pharmacogenetics 8:27-31 (1998).
127. Pemble S, Schroeder KR, Spencer SR, Meyer DJ, Hallier E, Bolt HM, Ketterer B, Taylor JB. Human glutathione S-transferase theta (GSTT1): cDNA cloning and the characterization of a genetic polymorphism. Biochem J 300:271-276 (1994).
128. Schröder KR, Hallier E, Peter H, Bolt HM. Dissociation of a new glutathione S-transferase activity in human erythrocytes. Biochem Pharmacol 43:1671-1674 (1992).
129. Norppa H, Hirvonen A, Järventaus H, Uusküla M, Tasa M, Ojajärvi A, Sorsa M. Role of GSTM1 and GSTT1 genotypes in determining individual sensitivity to sister chromatid exchange induction by diepoxybutane in cultured human lymphocytes. Carcinogenesis 16:1261-1264 (1995).
130. Wiencke JK, Pemble S, Ketterer B, Kelsey KT. Gene deletion of glutathione transferase theta. 1: correlation with induced genetic damage and potential role in endogeneous mutagenesis. Cancer Epidemiol Biomarkers Prev 4:253-260 (1995).
131. Saarikoski S, Voho A, Reinikainen M, Anttila S, Karjalainen A, Malaveille C, Vainio H, Husgafvel-Pursiainen K, Hirvonen A. Combined effect of polymorphic GST genes on individual susceptibility to lung cancer. Int J Cancer 77:516-521 (1998).
132. Jourenkova N, Reinikainen M, Bouchardy C, Dayer P, Benhamou S, Hirvonen A. Larynx cancer risk in relation to glutathione S-transferase M1 and T1 genotypes and tobacco smoking. Cancer Epidemiol Biomarkers Prev 7:19-23 (1988).
133. Deakin M, Elder J, Hendrickse C, Peckham D, Baldwin D, Pantin C, Wild N, Leopard P, Bell DA, Jones P, et al. Glutathione S-transferase GSTT1 genotypes and susceptibility to cancer: studies of interactions with GSTM1 in lung, oral, gastric and colorectal cancers. Carcinogenesis 17:881-884 (1996).
134. To-Figueras J, Gené M, Gómez-Catalán J. Galán MC, Fuentes M, Ramón JM, Rodamilans M, Huguet E, Corbella J. Glutathione S-transferase M1 (GSTM1) and T1 (GSTT1) polymorphisms and lung cancer risk among northwestern Mediterraneans. Carcinogenesis 18:1529-1533 (1997).
135. Kelsey K, Spitz MR, Zuo ZF, Wiencke JK. Polymorphisms in the glutathione S-transferase class mu and theta genes interact and increase susceptibility to lung cancer in minority populations. Cancer Causes Control 8:554-559 (1997).
136. Hirvonen A. Combinations of susceptible genotypes and individual responses to toxicants. Environ Health Perspect 105:755-758 (1997).
137. Evans, DA. N-Acetyltransferase. In: Pharmacogenetics of Drug Metabolism (Kalow W, ed). New York:Pergamon Press, 1992;95-178.
138. Hein DW, Doll MA, Rustan TD, Gray K, Feng Y, Fergyson RJ, Grant DM. Metabolic activation and deactivation of arylamine carcinogens by recombinant human NAT1 and polymorphic NAT2 acetyltransferases. Carcinogenesis 14:1633-1638 (1993).
139. Blum M, Grant DM, McBride W, Heim M, Meyer UA. Human arylamine N-acetyltransferase genes: isolation, chromosomal localization, and functional expression. DNA Cell Biol 9:193-203 (1990).
140. Hearse DJ, Weber WW. Multiple N-acetyltransferases and and drug metabolism. Tissue distribution, characterization and significance of mammalian N-acetyltransferase. Biochem J 132:519-526 (1973).
141. Coroneos E, Hickman D, Risch A, Kelly SL, Sim E. Arylamine N-acetyltransferase in cultured cell lines [Abstract]. J Basic Clin Physiol Pharmacol 3:5228 (1992).
142. Vatsis KP, Weber WW. Structural heterogeneity of Caucasian N-acetyltransferase at the NAT1 gene locus. Arch Biochem Biophys 301:71-76 (1993).
143. Grant DM, Blum M, Beer M, Meyer UA. Monomorphic and polymorphic human arylamine N-acetyltransferases: a comparison of liver isozymes and expressed products of two cloned genes. Mol Pharmacol 39:184-191 (1991).
144. Grant DM, Vohra P, Avis Y, Ima A. Detection of a new polymorphism of human arylamine N-acetyltransferase NAT1 using p-aminosalicylic acid as an in vivo probe [Abstract]. J Basic Clin Physiol Pharmacol 3:S244-(1992).
145. Hein DW, Rustan TD, Grant DM. Human liver polymorphic (NAT2) and monomorphic (NAT1) N-acetyltransferase isozymes catalyze metabolic activation of N-hydroxyarylamine and N-hydroxy-N-acetylarylamine proximate carcinogens [Abstract]. FASEB J 6:A1274 (1992).
146. Hein DW, Rustan TD, Doll MA, Bucher KD, Ferguson RJ, Feng Y, Furman EJ, Gray K. Acetyltransferases and susceptibility to chemicals. Toxicol Lett 64/65:123-130 (1992).
147. Lakshmi VM, Bell DA, Watson M, Zenser TV, Davis BB. N-Acetylbenzidine and N,N′-diacetylbenzidine formation by rat and human liver slices exposed to benzidine. Carcinogenesis 16:1565-1571 (1995).
148. Zenser TV, Lakshmi VM, Rustan TD, Doll MA, Deitz AC, Davis BB, Hein DW. Human N-acetylation of benzidine: role of NAT1 and NAT2. Cancer Res 56:3941-3947 (1996).
149. Grant DM, Vollmer K-O, Meyer UA. In vitro metabolism of dinaline and acetyldinaline by human liver. Abstracts of 12th European Workshop on Drug Metabolism, Basel, Switzerland. 147 (1990).
150. Grant DM, Hughes NC, Janezic SA, Goodfellow GH, Chen HJ, Gaedigk A, Yu VL, Grewal R. Human acetyltransferase polymorphisms. Mutat Res 376:61-70 (1997).
151. Vatsis KP, Weber WW, Bell DA, Dupret J-M, Evans DAP, Grant DM, Hein DW, Lin HJ, Meyer UA, Relling MV, et al. Nomenclature for N-acetyltransferases. Pharmacogenetics 5:1-17 (1995).
152. Bell DA, Badavi A, Lang N, llett KF, Kadlubar FF, Hirvonen A. Polymorphism in the NAT1 polyadenylation signal: association of NAT1*10 allele with higher N-acetylation activity in bladder and colon tissue samples. Cancer Res 55:5226-5229 (1995).
153. Badawi A, Hirvonen A, Bell DA, Lang N, Kadlubar FF. Role of aromatic amine acetyltransferases NAT1 and NAT2, in carcinogen-DNA adduct formation in the human urinary bladder. Cancer Res 55:5230-5237 (1995).
154. Fredrickson SM, Messing EM, Reznikoff CA, Swaminathan S. Relationship between in vivo acetylator phenotypes and cytosolic N-acetyltransferase and O-acetyltransferase activities in human uroepithelial cells. Cancer Epidemiol Biomarkers Prev 3:25-32 (1994).
155. Deitz AC, Doll MA, Hein DW. A restriction fragment length polymorphism assay that differentiates human N-acetyltransferase-1 (NAT1) alleles. Anal Biochem 253:219-224 (1997).
156. Doll MA, Jiang W, Deitz AC, Rustan TD, Hein DW. Identification of a novel allele at the human NAT1 acetyltransferase locus. Biochem Biophys Res Commun 233:584-591 (1997).
157. Lin H, Han C-Y, Lin BK, Hardy S. Ethnic distribution of slow acetylator mutations in the polymorphic N-acetyltransferase (NAT2) gene. Pharmacogenetics 4:125-134 (1994).
158. Bell DA, Stephens DA, Castranio T, Umbach DM, Watson M, Deakin M, Elder J, Hendrickse C, Duncan H, Strange RC. Polyadenylation polymorphism in the acetyltransferase 1 gene (NAT1) increases risk of colorectal cancer. Cancer Res 55:3537-3542 (1995).
159. Probst-Hensch NM, Haile RW, Li DS, Sakamoto GT, Louie AD, Lin BK, Frankl HD, Lee ER, Lin HJ. Lack of association between the polyadenylation polymorphism in the NAT1 (acetyltransferase 1) gene and colorectal adenomas. Carcinogenesis 17:2125-2129 (1996).
160. Bouchardy C, Mitrunen K, Wikman H, Husgafvel-Pursiainen K, Dayer P, Benhamou S, Hirvonen A. N-Acetyltransferase NAT1 and NAT2 genotypes and lung cancer risk. Pharmacogenetics 8:291-298 (1998).
161. Weber WW. The Acetylator Genes and Drug Response. New York:Oxford University Press, 1987.
162. Lin H, Man C-Y, Lin BK, Hardy S. Slow acetylator mutations in the human polymorphic N-acetyltransferase gene in 786 Asians, Blacks, Hispanics, and Whites: application to metabolic epidemiology. Am J Hum Genet 52:827-834 (1993).
163. Cascorbi I, Drakoulis N, Brockmöller J, Maurer A, Sperling K, Roots I. Arylamine N-acetyltransferase (NAT2) mutations and their allelic linkage in unrelated Caucasian individuals: correlation with phenotypic. Am J Hum Genet 57:581-592 (1995).
164. Mrozikiewicz PM, Drakoulis N, Roots I. Polymorphic arylamine N-acetyltransferase (NAT2) genes in children with insulin-dependent diabetes mellitus. Clin Pharmacol Ther 56:626-634 (1994).
165. Hirvonen A, Pelin K, Tammilehto L, Karjalainen A, Mattson K, Linnainmaa K. Inherited GSTM1 and NAT2 defects as concurrent risk modifiers for asbestos-associated human malignant mesothelioma. Cancer Res 55:2981-2983 (1995).
166. Mashimo M, Suzuki T, Abe M, Deguchi T. Molecular genotyping of N-acetylation polymorphism to predict phenotype. Hum Genet 90:139-142 (1992).
167. Rothman N, Hayes RB, Bi W, Caporaso N, Broly F, Woosley RL, Yin S, Feng P, You X, Meyer UA. Correlation between N-acetyltransferase activity and NAT2 genotype in Chinese males. Pharmacogenetics 3:250-255 (19939.
168. Hirvonen A (1998) Polymorphic NATs and cancer proneness. In: Metabolic Polymorphisms and Cancer (Boffetta P, Caporaso N, Cuzick J, Lang M, Vineis P, eds). IARC Sci Publ No 148. Lyon: International Agency for Research on Cancer, in press.
169. Weber WW, Mattano SS, Levy GN. Acetylator pharmacogenetics and aromatic amine-induced cancer. In: Carcinogenic and Mutagenic Responses to aAromatic Amines and Nitroarenes (King CM, ed). New York:Elsevier; 1988;115-123.
170. Kadlubar FF, Butler MA, Kaderlik KR, Chou HC, Lang NP. Polymorphisms for aromatic amine metabolism in humans: relevance for human carcinogenesis. Environ Health Perspect 98:69-74 (1992).
171. Risch A, Wallace DMA, Bathers S, Sim E. Slow N-acetylation genotype is a susceptibility factor in occupational and smoking related bladder cancer. Hum Mol Genet 4: 231-236 (1995).
172. Golka K, Prior V, Blaszkewicz M, Cascorbi I, Schöps W, Kierfeld G, Roots I, Bolt HM. Occupational history and genetic N-acetyltransferase polymorphism in urothelial cancer patients of Leverkusen, Germany. Scand J Work Environ Health 22:332-338 (1996).
173. Evans DAP, Eze LC, Whitney EJ. The association of the slow acetylator phenotype with bladder cancer. J Med Genet 20:330-333 (1983).
174. Taylor JA, Umbach D, Stephens E, Castranio T, Paulson D, Robertson C, Mohler JL, Bell DA. The role of N-acetylation polymorphism in smoking associated bladder cancer: evidence of a gene-gene exposure three-way interaction. Cancer Res 58:3603-3610 (1998).
175. Turesky RJ, Lang NP, Butler MA, Teitel CH, Kadlubar FF. Metabolic activation of carcinogenic heterocyclic aromatic amines by human liver and colon. Carcinogenesis 12:1839-1845 (1991).
176. Giovannucci E, Rimm EB, Stampfer MJ, Hunter D, Rosner B, Willett WC, Speizer FE. A prospective study of cigarette smoking and risk of colorectal adenoma and colorectal cancer in US men. J Natl Cancer Inst 86:183-191 (1994).
177. Giovannucci E, Willett WC. Dietary factors and risk of colon cancer, Ann Med 26:443-452 (1994).
178. Minchin RF, Reeves PT, Teitel CH, McManus ME, Mojarrabbi B, llett KF, Kadlubar FF. N-and O-acetylation of aromatic and heterocyclic amine carcinogens in by human monomorphic and polymorphic acetyltransferase expressed in cos-1 cells. Biochem Biophys Res Commun 185:839-844 (1992).
179. Yanagawa Y, Sawada M, Deguchi T, Gonzalez FJ, Kamataki T. Stable expression of human CYP1A2 and N-acetyltransferases in Chinese hamster CHL cells: mutagenic activation of 2-amino-3-methylimidazo[4,5-f]quinoline and 2-amino-3,8-dimethylimidazo[4,5]-f-quino-xaline. Cancer Res 54:3422-3427 (1994).
180. Wild D, Fesrs W, Michel S, Lord HL, Josephy PD. Metabolic activation of heterocyclic aromatic amines catalyzed by human arylamine N-acetyltransferase isozymes (NAT1 and NAT2) expressed in Salmonella typhimurium. Carcinogenesis 16:643-548 (1995).
181. Yokoi T, Sawada M, Kamataki T. Polymorphic drug metabolism: studies with recombinant Chinese hamster cells and analyses in human populations. Pnarmacogenetics 5.S65-S69 (1995).
182. Chen J, Stampfer MJ, Hough HL, Garcia-Closas M, Willett WC, Hennekens CH, Kelsey KT, Hunter DJ. A prospective study of N-acetyltransferase genotype, red meat intake, and risk of colorectal cancer. Cancer Res 58:3307-3311 (1998).
183. Ambrosone CB, Freudenheim JL, Graham S, Marshall JR, Vena JR, Brasure JR, Michalek AM, Laughlin R, Nemoto T, Gillenwater KA, et al. Cigarette smoking, N-acetyltransferase, genetic polymorphisms, and breast cancer risk. JAMA 276:1494-1501 (1995).
184. Hunter DJ, Hankinson SE, Hough H, Gertig DM, Garcia-Closas M, Spiegelman D, Manson JE, Colditz GA, Willett WC, Speizer FE, et al. A prospective study of NAT2 acetylation genotype, cigarette smoking, and risk of breast cancer. Carcinogenesis 18:2127-2132 (1997).
185. Millikan RC, Pittman GS, Newman B, Tse CKJ, Selmin O, Rockhill B, Savitz DS, Moorman PG, Bell DA. Cigarette smoking, N-acetyltransferases 1 and 2, and breast cancer risk. Cancer Epidemiol Biomarker Prev 7:371-378 (1998).
186. Martínez C, Agúndez JAG, Olivera M, Martín R, Ladero JM, Benítez J. Lung cancer and mutations at the polymorphic NAT2 gene locus. Pharmacogenetics 5:207-214 (1995).
187. Cascorbi I, Brockmöller J, Mrozikiewicz PM, Bauer S, Loddenkemper R, Roots I. Homozygous rapid arylamine N-acetyltransferase (NAT2) genotype as a susceptibility factor for lung cancer. Cancer Res 56:3961-3966 (1996).
188. Saarikoski ST, Reinikainen M, Anttila S, Karjalainen A, Vainio H, Husgafvel-Pursiainen K, Hirvonen A. Role of NAT2 deficiency in susceptibility to lung cancer among asbestos-exposed individuals. Pharmacogenetics (in press).
189. Hirvonen A, Saarikoski S, Linnainmaa K, Koskinen K, Husgafvel-Pursiainen K, Vainio H. GST and NAT genotypes and asbestos-associated pulmonary disorders. J Natl Cancer Inst 88:1853-1856 (1396)
190. Agúndez JAG, Oliveta M, Martinez C, Ladero JM, Benítez J. Identification and prevalence study of 17 allelic variants of the human NAT2 gene in a white population. Pharmacogenetics 6:423-428 (1996).
191. Joseph P, Xie T, Xu Y, Jaiswal AK. NAD(P)H: quinone oxidoreductase 1 (DT-diaphorase): expression, regulation and role in cancer. Oncol Res 6:525-532 (1994).
192. Lind C, Cadenas E, Hochstein P, Ernster L. DT-diaphorase: purification, properties and function. Methods Enzymol 186:287-301 (1990).
193. Traver RD, Horikoshi T, Danenberg PV, Ross D, Gibson NW. NAD(P)H:quinone oxidoreductase gene expression in human colon carcinoma cells: characterization of mutation which modulates DT-diaphorase activity and mitomycin sensitivity. Cancer Res 52:797-802 (1992).
194. Eickelman P, Schulz WA, Rohde D, Schmitz-Drager B, Sies H. Loss of heterozygosity at the NAD(P)H:quinone oxidoreductase locus associated with increased resistance against mitomycin C in human bladder carcinoma cell line. Biol Chem Hoppe Seyler 375:439-445 (1994).
195. Rosvold EA, McGlynn KA, Lustbader ED, Buetow KH. Identification of an NAD(P)H: quinone oxidoreductase polymorphism and its association with lung cancer and smoking. Pharmacogenetics 5:199-206 (1995).
196. Schulz WA, Krummeck A, Rösinger I, Eickelmann P, Neuhaus C, Eben T, Schmitz-Dräger BJ, Sies H. Increased frequency of a null-allele for NAD(P)H:quinone oxidoreductase in patients with urological malignancies. Pharmacogenetics 7:235-239 (1997).
197. Marshall RS, Paterson MC, Rauth AM. DT-diaphorase activity and mitomycin C sensitivity in non-transformed cell strains derived from members of a cancer-prone family. Carcinogenesis 12:1175-1180 (1991).
198. Kolesar JM, Kuhn JG, Burris HA III. Detection of a point mutation in NQO1 (DT-diaphorase) in a patient with colon cancer. J Natl Cancer Inst 87:1022-1024 (1995).
199. Hunninghake GW, Crystal RG. Cigarette smoking and lung destruction: accumulation of neutrophils in the lungs of cigarette smokers. Annu Rev Respir Dis 128:833-838 (1990).
200. Schmekel B, Hornblad Y, Linden M, Sundström C, Venge P. Myeloperoxidase in human lung lavage. II: Internalization of myeloperoxidase by alveolar macrophages. Inflammation 14: 455-461 (1990).
201. Schmekel B, Karlsson SE, Linden M, Sundström C, Tenge H, Venge P. Myeloperoxidase in human lung lavage. I: A marker of local neutrophil activity. Inflammation 14:447-454 (1990).
202. Mallet WG, Mosebrook DR, Trush MA. Activation of (±)-trans-7,8-dihydroxy-7,8-dihydrobenzo[a]pyrene to diolepoxides by human polymorphonuclear leucocytes or myeloperoxidase. Carcinogenesis 12:521-524 (1991).
203. London SJ, Lehman TA, Taylor JA. Myeloperoxidase genetic polymorphism and lung cancer risk. Cancer res 57:5001-5003 (1997).
204. Michejda CJ, Kroeger, Koepke MB. Carcinogen activation by sulfate conjugate formation. Adv Pharmacol 27:331-363 (1994).
205. Jin CJ, Miners JO, Burchell B, MacKenzie PI. The glucuronidation of hydroxylated metabolites of benzo(a)pyrene and 2-acetylaminofluorene by cDNA expressed human UDP-glucuronocyltransferases. Carcinogenesis 14:2637-2639 (1993).
206. Mackenzie Pi, Rodbourn L, Iyanagi T. Glucuronidation of carcinogen metabolites by complementary DNA-expressed uridine 5′-diphosphate glucuronocyltransferases. Cancer Res 53:1529-1533 (1993).
207. Babu SR, Lakshmi VM, Owens IS, Zenser TV, Davis BB. Human liver glucuronidation of benzidine. Carcinogenesis 15:2003-2007 (1994).
208. Owens IS, Ritter JK. Gene structure at the human UGT1 locus creates diversity in isozyme structure, substrate specificity, and regulation. Prog Nucleic Acid Res Mol Biol 51:205-338 (1995).
209. Hines RN, Cashman JR, Philpot RM, Williams DE, Ziegler DM. The mammalian flavin-containing monooxygenases: molecular characterization and regulation of expression. Toxicol Appl Pharmacol 125:1-6 (1994).
210. Philips IR, Dolphin CT, Clair P, Hadley MR, Hutt AJ, McCombie RR, Smith RL, Shephard EA. The molecular biology of the flavin-containing monooxygenases of man. Chem-Biol Interact 96:17-32 (1995).
211. Humbert R, Adler DA, Disteche CM, Hasset C, Omiecinski CJ, Furlong CE. The molecular basis of human serum paraoxonase activity polymorphism. Nat Genet 3:73-76 (1993).
212. Furlong CE, Costa LG, Hasset C, Richter RJ, Sundström JA, Adler DA, Disteche CM, Omiecinski CJ, Chapline C, Crabb JW. Human and rabbit paraoxonases: purification, cloning, sequencing, mapping and role of polymorphism in organophosphate detoxification. Chem-Biol Interact 87:35-48 (1993).